Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2002.06.037 on July 1 2002

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berenson, J. R.
Right arrow Articles by Biermann, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berenson, J. R.
Right arrow Articles by Biermann, J. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 17 (September), 2002: 3719-3736
© 2002 American Society for Clinical Oncology

ASCO SPECIAL ARTICLE

American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma

By James R. Berenson, Bruce E. Hillner, Robert A. Kyle, Ken Anderson, Allan Lipton, Gary C. Yee, J. Sybil Biermann for the American Society of Clinical Oncology Bisphosphonates Expert Panel

From the American Society of Clinical Oncology, Health Services Research Department, Alexandria, VA.

This article was published ahead of print at www.jco.org.Address reprint requests to: American Society of Clinical Oncology, Health Services Research Department, 1900 Duke St, Suite 200, Alexandria, VA 22314; email: guidelines{at}asco.org

PURPOSE: To determine clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of lytic bone disease in multiple myeloma and to determine their respective role relative to other conventional therapies for this condition.

METHODS: An expert multidisciplinary Panel reviewed pertinent information from the published literature through January 2002. Values for levels of evidence and grade of recommendation were assigned by expert reviewers and approved by the Panel. Expert consensus was used if there were insufficient published data. The Panel addressed which patients to treat and when to treat them in the course of their disease. Additionally, specific drug delivery issues, duration of therapy, initiation of treatment and management of treatment of lytic bone disease was reviewed and compared with other forms of therapy for lytic bone lesions. Finally, the Panel discussed patient and physician expectations associated with this therapy for bony metastases, as well as public policy implications related to the use of bisphosphonates. The guidelines underwent external review by selected physicians, by the Health Services Research Committee members, and by the ASCO Board of Directors.

RESULTS: The available evidence involving randomized controlled trials is modest but supports that oral clodronate, intravenous pamidronate, and intravenous zoledronic acid are superior to placebo in reducing skeletal complications. A reduction in vertebral fractures has consistently been seen across all studies. No agent has shown a definitive survival benefit. Intravenous zoledronic acid has recently been shown to be as effective as intravenous pamidronate. Because there are no direct comparisons between clodronate and pamidronate or zoledronic acid, the superiority of one agent cannot be definitively established. However, the panel recommends only intravenous pamidronate or zoledronic acid in light of the use of the time to first skeletal event as the primary end point and more complete assessment of bony complications in studies evaluating it. Additionally, clodronate is not available in the United States. The choice between pamidronate and zoledronic acid will depend on choosing between the higher drug cost of zoledronic acid, with its shorter, more convenient infusion time (15 minutes), versus the less expensive drug, pamidronate, with its longer infusion time (2 hours).

CONCLUSION: Bisphosphonates provide a meaningful supportive benefit to multiple myeloma patients with lytic bone disease. However, further research on bisphosphonates is warranted, including the following: (1) when to start and stop therapy, (2) how to integrate their use with other treatments for lytic bone disease, (3) how to evaluate their role in myeloma patients without lytic bone involvement, (4) how to distinguish between symptomatic and asymptomatic bony events, and (5) how to better determine their cost-benefit consequence.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Pozzi, S. Vallet, S. Mukherjee, D. Cirstea, N. Vaghela, L. Santo, E. Rosen, H. Ikeda, Y. Okawa, T. Kiziltepe, et al.
High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties
Clin. Cancer Res., September 15, 2009; 15(18): 5829 - 5839.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al.
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Ann. Onc., August 1, 2009; 20(8): 1303 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Fizazi, A. Lipton, X. Mariette, J.-J. Body, Y. Rahim, J. R. Gralow, G. Gao, L. Wu, W. Sohn, and S. Jun
Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
J. Clin. Oncol., April 1, 2009; 27(10): 1564 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. Van den Wyngaert, M. T. Huizing, E. Fossion, and J. B. Vermorken
Bisphosphonates in Oncology: Rising Stars or Fallen Heroes
Oncologist, February 1, 2009; 14(2): 181 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. T. Drake, B. L. Clarke, and S. Khosla
Bisphosphonates: Mechanism of Action and Role in Clinical Practice
Mayo Clin. Proc., September 1, 2008; 83(9): 1032 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 cfpHome page
A. Khan
Bisphosphonate-associated osteonecrosis of the jaw
Can Fam Physician, July 1, 2008; 54(7): 1019 - 1021.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Raje, S.-B. Woo, K. Hande, J. T. Yap, P. G. Richardson, S. Vallet, N. Treister, T. Hideshima, N. Sheehy, S. Chhetri, et al.
Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw
Clin. Cancer Res., April 15, 2008; 14(8): 2387 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. B. Dodson, N. S. Raje, P. A. Caruso, and A. E. Rosenberg
Case 9-2008 -- A 65-Year-Old Woman with a Nonhealing Ulcer of the Jaw
N. Engl. J. Med., March 20, 2008; 358(12): 1283 - 1291.
[Full Text] [PDF]

Home page
 JDRHome page
S.L. Ruggiero and S.J. Drew
Osteonecrosis of the Jaws and Bisphosphonate Therapy
Journal of Dental Research, November 1, 2007; 86(11): 1013 - 1021.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Z. Orlowski, A. Nagler, P. Sonneveld, J. Blade, R. Hajek, A. Spencer, J. San Miguel, T. Robak, A. Dmoszynska, N. Horvath, et al.
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
J. Clin. Oncol., September 1, 2007; 25(25): 3892 - 3901.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. T. Petrucci, C. Gallucci, A. Agrillo, M. C. Mustazza, and R. Fo
Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients
Haematologica, September 1, 2007; 92(9): 1289 - 1290.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Terpos, O. Sezer, P. Croucher, and M.-A. Dimopoulos
Myeloma bone disease and proteasome inhibition therapies
Blood, August 15, 2007; 110(4): 1098 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. Bergner, D. M. Henrich, M. Hoffmann, A. Honecker, G. Mikus, B. Nauth, D. Nagel, and M. Uppenkamp
Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function
J. Clin. Pharmacol., August 1, 2007; 47(8): 942 - 950.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
C. D Krueger, P. M West, M. Sargent, A. E Lodolce, and A S. Pickard
Bisphosphonate-Induced Osteonecrosis of the Jaw
Ann. Pharmacother., February 1, 2007; 41(2): 276 - 284.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Tosi, E. Zamagni, D. Cangini, P. Tacchetti, F. Di Raimondo, L. Catalano, A. D'Arco, S. Ronconi, C. Cellini, M. Offidani, et al.
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Blood, December 15, 2006; 108(12): 3951 - 3952.
[Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. L de Lemos, S. C Taylor, J. B Barnett, F. Hu, A. Levin, V. Moravan, and S. E O'Reilly
Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database
Journal of Oncology Pharmacy Practice, December 1, 2006; 12(4): 193 - 199.
[Abstract] [PDF]

Home page
 CJASNHome page
S. Singhal and J. Mehta
Multiple Myeloma
Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1322 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. S. Yeh and J. R. Berenson
Treatment for myeloma bone disease.
Clin. Cancer Res., October 15, 2006; 12(20): 6279s - 6284s.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Sanna, L Preda, R Bruschini, M Cossu Rocca, S Ferretti, L Adamoli, E Verri, L Franceschelli, A Goldhirsch, and F Nole
Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer
Ann. Onc., October 1, 2006; 17(10): 1512 - 1516.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
M. R. Smith
Bisphosphonates for Metastatic Bone Disease -- Too Much of a Good Thing?
IBMS BoneKEy, September 1, 2006; 3(9): 24 - 27.
[Full Text] [PDF]

Home page
 Ann OncolHome page
T. Van den Wyngaert, M. T. Huizing, and J. B. Vermorken
Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?
Ann. Onc., August 1, 2006; 17(8): 1197 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. Q. Lacy, A. Dispenzieri, M. A. Gertz, P. R. Greipp, K. L. Gollbach, S. R. Hayman, S. Kumar, J. A. Lust, S. V. Rajkumar, S. J. Russell, et al.
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
Mayo Clin. Proc., August 1, 2006; 81(8): 1047 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Tanvetyanon and P. J. Stiff
Management of the adverse effects associated with intravenous bisphosphonates
Ann. Onc., June 1, 2006; 17(6): 897 - 907.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
E. Carneiro, P. Vibhute, A. Montazem, and P.M. Som
Bisphosphonate-associated mandibular osteonecrosis.
AJNR Am. J. Neuroradiol., May 1, 2006; 27(5): 1096 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Badros, D. Weikel, A. Salama, O. Goloubeva, A. Schneider, A. Rapoport, R. Fenton, N. Gahres, E. Sausville, R. Ord, et al.
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
J. Clin. Oncol., February 20, 2006; 24(6): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
C. Van Poznak
Osteonecrosis of the Jaw
J. Oncol. Pract, January 1, 2006; 2(1): 3 - 4.
[Full Text] [PDF]

Home page
 J Oncol PractHome page
S. Ruggiero, J. Gralow, R. E. Marx, A. O. Hoff, M. M. Schubert, J. M. Huryn, B. Toth, K. Damato, and V. Valero
Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer
J. Oncol. Pract, January 1, 2006; 2(1): 7 - 14.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. Z. Orlowski
Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation
Hematology, January 1, 2006; 2006(1): 338 - 347.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Bamias, E. Kastritis, C. Bamia, L. A. Moulopoulos, I. Melakopoulos, G. Bozas, V. Koutsoukou, D. Gika, A. Anagnostopoulos, C. Papadimitriou, et al.
Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
J. Clin. Oncol., December 1, 2005; 23(34): 8580 - 8587.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Dental AssociationHome page
M. D. MELO and G. OBEID
Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition
J Am Dent Assoc, December 1, 2005; 136(12): 1675 - 1681.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. D. Michaelson and M. R. Smith
Bisphosphonates for Treatment and Prevention of Bone Metastases
J. Clin. Oncol., November 10, 2005; 23(32): 8219 - 8224.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Miwa, A. Mizokami, E. T. Keller, R. Taichman, J. Zhang, and M. Namiki
The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4-Induced Invasion in Prostate Cancer
Cancer Res., October 1, 2005; 65(19): 8818 - 8825.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. V. Rajkumar and R. A. Kyle
Multiple Myeloma: Diagnosis and Treatment
Mayo Clin. Proc., October 1, 2005; 80(10): 1371 - 1382.
[Abstract] [PDF]

Home page
 Ann OncolHome page
E. Terpos and M.-A. Dimopoulos
Myeloma bone disease: pathophysiology and management
Ann. Onc., August 1, 2005; 16(8): 1223 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Balla
The Issue of Renal Safety of Zoledronic Acid from a Nephrologist's Point of View
Oncologist, May 1, 2005; 10(5): 306 - 308.
[Full Text] [PDF]

Home page
 The OncologistHome page
P. Conte and V. Guarneri
In Response to Jackson Letter to the Editor Regarding "Safety of Intravenous and Oral Bisphosphonates and Compliance with Dosing Regimens"
Oncologist, May 1, 2005; 10(5): 315 - 316.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. L. Olson, L. C. Burkly, D. R. Leone, B. M. Dolinski, and R. R. Lobb
Anti-{alpha}4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model
Mol. Cancer Ther., January 1, 2005; 4(1): 91 - 99.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. R. Berenson
Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases
Oncologist, January 1, 2005; 10(1): 52 - 62.
[Abstract] [Full Text] [PDF]

Home page
 J Am Board Fam MedHome page
F. Rainone
Treating Adult Cancer Pain in Primary Care
J Am Board Fam Med, November 1, 2004; 17(suppl_1): S48 - S56.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al.
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
J. Clin. Oncol., November 1, 2003; 21(21): 4042 - 4057.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Musto, A. Falcone, G. Sanpaolo, C. Bodenizza, and A. M. Carella
Pamidronate for Early-Stage, Untreated Myeloma
J. Clin. Oncol., August 15, 2003; 21(16): 3177 - 3178.
[Full Text] [PDF]

Home page
 JBJSHome page
K. L. Weber and M. C. Gebhardt
What's New in Musculoskeletal Oncology
J. Bone Joint Surg. Am., March 31, 2003; 85(4): 761 - 767.
[Full Text] [PDF]

Home page
 J Am Acad Orthop SurgHome page
J. T. Lin and J. M. Lane
Bisphosphonates
J. Am. Acad. Ortho. Surg., January 1, 2003; 11(1): 1 - 4.
[Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
K. C. Anderson
Multiple Myeloma: How Far Have We Come?
Mayo Clin. Proc., January 1, 2003; 78(1): 15 - 17.
[PDF]

Home page
 Mayo Clin Proc.Home page
S. V. Rajkumar, M. A. Gertz, R. A. Kyle, and P. R. Greipp
Use of Bisphosphonates in Patients With Myeloma and Renal Failure-Reply-I
Mayo Clin. Proc., January 1, 2003; 78(1): 118 - 118.
[PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online